Epidemiology and clinical features of Birt-Hogg-Dubé syndrome: A nationwide population-based study in South Korea.

BACKGROUND: Birt-Hogg-Dubé (BHD) syndrome is an ultrarare lung disease with unclear prevalence and incidence. Our study aimed to identify the epidemiological and clinical features of BHD syndrome by using nationwide claims data from the Korean Health Insurance Review and Assessment service.
METHODS: Patients with BHD syndrome who had the following criteria were included: 1) tested for folliculin gene mutation, and 2) had at least one of the conditions: other specified malformation syndromes, fibrofolliculoma, acrochordon, lung cyst, cancer, and pneumothorax based on International Classification of Disease-10 code.
RESULTS: We found 26 patients with BHD syndrome from 2017 to 2019. The prevalence of BHD syndrome was 5.67 per 107 population, with no peak age. Among incidence cases, the median age of diagnosis was 51 years, with slightly more females than males (n = 15, 57.7%). Over half of the patients (n = 14, 53.8%) experienced pneumothorax, and 10 (38.5%) developed malignant neoplasm within the clinical course.
CONCLUSIONS: The prevalence of BHD syndrome in Korea is extremely low. However, affected patients manifest several comorbidities, including malignant neoplasm and repetitive pneumothorax.

Introduction

Birt–Hogg–Dubé (BHD) syndrome is a rare inherited autosomal dominant disorder [1]. It is believed to be caused by the germline mutation of folliculin (FLCN) gene [2, 3]. However, the exact pathogenesis and function of FLCN remains unknown. Although FLCN mutations are often found in affected family members [4, 5], de novo development of BHD syndrome with no prior family history can also occur [6].

Typically, BHD syndrome is characterized by skin lesion, renal cancer, cystic lung disease, and spontaneous pneumothorax [7]. However, the spectrum, onset time, and frequency of these clinical manifestations are diverse, making the diagnosis difficult [8, 9]. In addition, the genetic, epidemiologic, and clinical characteristics of BHD syndrome might differ between Asian and Western populations [10, 11]. Currently, the nationwide data about its incidence, prevalence, and accompanying comorbidities are unavailable. Thus, this study aimed to investigate the epidemiologic data and clinical characteristics of BHD syndrome by using the nationwide claims data of Korea.

Materials and methods

Study design and data collection

This nationwide retrospective cohort study enrolled patients diagnosed with BHD who also had an ICD-10 code and an insurance payment code. In South Korea, the National Health Insurance Service is a universal insurance system that provides both inpatient and outpatient healthcare services for nearly all citizens, which enables to the investigation of the prevalence of disease in the whole national population [12, 13]. Similar to previous code-based nationwide research, we conducted an analysis based on ICD-10 codes [14, 15]. Considering its extreme rarity, the BHD syndrome does not have its own ICD-10 code; rather, it belongs to the ICD code Q878, which includes Alport syndrome, arterial tortuosity syndrome, and other congenital malformation diseases. Moreover, the confirmation test, that is, the FLCN gene test, is not common; thus, it was included in the code C5808. S1 Table lists the tests included in C5808. Patients with BHD syndrome in Korea are under the insurance policy for incurable rare diseases, which have distinct codes. However, given that BHD syndrome is rare, it is included in the rare incurable disease code V900, which consists of 127 diseases (S2 Table). Considering this limitation, the BHD syndrome was also defined using the insurance payment code for FLCN gene (C5808) and the comorbidities according to the corresponding ICD codes.

From the Health Insurance and Review Agency (HIRA) database between January 2007 and October 2019, we extracted patients undergoing FLCN gene tests using national health insurance payment code (C5808) after 2016 and subclass of gene test (C5808446) after 2017. As the presentation can differ among patients due to different disease onsets per organ, we defined BHD patients as those tested for FLCN gene mutation (C5808446) and having at least one of: other specified malformation syndromes (Q87.8), fibrofolliculoma (D23), acrochordon (L918), lung cyst (Q330), renal cancer (C64, C65, and cancer registration code (V027, V193, and V194)), and pneumothorax (J93) based on International Classification of Disease-10 (ICD-10). For distinction from other cystic lung diseases, the following diseases were excluded: Langerhans cell histiocytosis (J848) and lymphangioleiomyomatosis (D181). In BHD patients, demographic characteristics and associated diseases including malignancy were described. To identify the diseases associated with BHD syndrome, we extracted diagnoses within 1 year before and after the FLCN gene mutation test. To protect individual privacy, anonymized and de-identified information was analyzed. To quantity pneumothorax in BHD syndrome, patient-wise pattern of hospitalization was depicted throughout the entire studied period.

Ethics approval and consent to participate

Not required, because this study only use publicly available Health Insurance and Review Agency database.

Statistical methods

The patients’ age was described using median and 25% and 75% quantiles. To understand the natural course of cancer risks, we showed the cumulative incidence using number and percentage. As the number of included patients was small, we could not evaluate group differences by usual methods [16]. The temporal relationship between the date of FLCN gene claim and pneumothorax, which is a clue for diagnosing BHD, is shown in Fig 1.

Fig 1

Hospitalization for pneumothorax compared with date of BHD diagnosis.

The figure shows the onset and in-hospital period for pneumothorax per patient. The month zero is defined by the day of BHD diagnosis, and the shaded area is the previous 3 months of the diagnosis. The hospital admission period is depicted as the length of each bar.

Results

Prevalence of BHD syndrome

Although the FLCN gene test was introduced in 2014 in South Korea, this test was first claimed in January 2016. In the database, 26 patients had BHD syndrome (5.67 per 10 million). Among them, the number and prevalence by sex were 11 and 5.67 (95% CI: 3.71–8.32) in males and 15 and 6.60 (95% CI: 3.7–10.9) in females, respectively. BHD syndrome tended to develop more in females than in males. The median (interquartile range) age was 51 (34–58) years, with 46 (30–57) years in males and 53.5 (31–59) years in females specifically. Moreover, 11 of 26 patients (42.3%) with BHD syndrome underwent FLCN gene test around 50–59 years of age and 8 of 26 (30.8%) patients were tested around 30–49 years of age. The distribution of diagnosis age according to sex is described in Table 1.

Table 1

The number of BHD patients according to age group and sex.

Age group	Total		Male		Female
	N	Prevalence 95% CI	N	Prevalence 95% CI	N	Prevalence 95% CI
10–19	1	2.01 (0.05–11.2)	0	0 NA	1	4.18 (0.11–23.3)
20–29	3	4.40 (0.91–12.8)	2	5.58 (0.68–20.1)	1	3.09 (0.08–17.2)
30–39	4	5.65 (1.54–14.4)	2	5.50 (0.67–19.9)	2	5.81 (0.7–21)
40–49	4	4.77 (1.3–12.22)	2	4.69 (0.57–16.9)	2	4.85 (0.59–17.5)
50–59	11	12.69 (6.34–22.7)	4	9.16 (2.5–23.4)	7	16.27 (6.54–33.5)
60–69	2	3.16 (0.38–11.4)	1	3.24 (0.08–18.0)	1	3.10 (0.08–17.2)
70–79	1	2.78 (0.07–15.4)	0	0 NA	1	5.02 (0.13–28.0)
total	26	5.67 (3.71–8.32)	11	4.76 (2.38–8.52)	15	6.60 (3.7–10.9)

NA: Not applicable; N: Number of BHD patients; Prevalence: calculated per 10 million

Comorbidities

Among the 26 BHD patients, 10 patients had malignancy in this cohort observational period. Among the patients, nine (34.6%) had malignancy before the FLCN gene test and one was diagnosed with cancer after this test (Table 2). In terms of cancer subtypes, digestive cancer (15.4%) and urologic cancer (11.5%) showed the first and second highest incidence before and after BHD syndrome diagnosis, respectively. Lip and orophaynx, thoracic, genital, and hematologic cancers were also identified. Table 3 summarizes the associated diseases identified within 1 year before and after the FLCN gene test. The common comorbidities other than respiratory disease according to organ were gingivitis and periodontal disease (84%) and gastritis and duodenitis (88%). We also found gastroesophageal reflux disease (65.4%), ophthalmic disease (53.8%), dyslipidemia (53.8%), allergic contact dermatitis (42.3%), and hypertension (38.5%) (Table 3). Meanwhile, four patients (16%) had fibrofolliculoma identified within 1 year of the FLCN gene test.

Table 2

Associated malignancy in patients with BHD syndrome before and after folliculin gene test.

ICD-10 code	Cancer type	Before (N = 26)	After (N = 26)	Total (N = 26)
C00–C97	All kinds of malignancy	9 (34.6%)	1 (3.8%)	10 (38.5%)
C15–C26	Digestive	3 (11.5%)	1 (3.8%)	4 (15.4%)
C64–C68	Ureter and bladder	3 (11.5%)	0 (0%)	3 (11.5%)
C00– C14	Lip and oropharynx	2 (7.7%)	0 (0%)	2 (7.7%)
C30–C39	Respiratory and intrathoracic	1 (3.8%)	0 (0%)	1 (3.8%)
C51–C63	Genital	1 (3.8%)	0 (0%)	1 (3.8%)
C81–C96	Hematologic	1 (3.8%)	0 (0%)	1 (3.8%)

The date of malignancy contains all periods of the patients before and after the folliculin gene mutation test.

Table 3

Associated diseases before and after the diagnosis of BHD syndrome.

ICD-10 code	Associated disease	Total (N = 26) (Number, %)
K29	Gastritis and duodenitis	23 (88.5%)
J00-98	Upper respiratory disease	23 (88.5%)
K02-05	Gingivitis and periodontal disease	22 (84.6%)
J20	Acute bronchitis	18 (69.2%)
K21	Gastroesophageal reflux disease	17 (65.4%)
J93	Pneumothorax	14 (53.8%)
H04, H10, H52	Ophthalmic disease	14 (53.8%)
E78	Dyslipidemia	14 (53.8%)
L03, L23, L50, M79	Skin disease	11 (42.3%)
J84	Other interstitial lung diseases	10 (38.5%)
I10	Hypertension	10 (38.5%)

The date of the associated disease contains only within 1 year before and after the folliculin gene test. Upper respiratory disease includes following codes: J00, J01, J02, J03, J04, J06, J20, J30, J40, J44, and J98.

Pneumothorax

During the study period, 17 (65.4%) patients suffered at least one pneumothorax, 10 of whom (58.8%) had recurrent pneumothorax (Table 4). Pneumothorax was more common in females than in males (11, 64.7% vs. 6, 35.2%). The median age of patients at pneumothorax diagnosis was 43 (31–57) years (25%–75%), with 40 (28–57) years in males and 43 (34–55) years in females specifically. Pneumothorax occurring more than once was found in 5 of 6 male patients (83%) and in 5 of 11 female patients (45%). In those with at least one pneumothorax event, the mean (standard deviation) length of hospital stay was 9.9 (6.1) days in the first event and 12.6 (6.8) days in the second event. All the patients with recurrent pneumothorax (n = 10), no patients underwent surgery and 70% (n = 7/10) were treated with chest tube insertion. The median length of hospital stay by sex was 8 (6.5–13) in males and 9.5 (5.75–15.25) in females. Pneumothorax that occurred within 3 months of BHD syndrome diagnosis was found in 13 of all 26 patients (Fig 1). The median (interquartile range) time from pneumothorax to BHD syndrome diagnosis was 39 (5.4–98) months.

Table 4

Number of pneumothoraxes among BHD patients.

Number of pneumothoraxes	Number of patients	%
0	9
1	7	26.9%
2	9	34.6%
>3	1	3.8%
Total	26

Discussion

The current study is the first population-based research performed on the prevalence of BHD syndrome in Korea by using a nationwide claims database. Although the prevalence of BHD syndrome was extremely rare in South Korea (5.67 per 10 million), various comorbidities, including malignancy and repetitive pneumothorax, were found.

Given that the BHD syndrome is a rare inherited disorder [17], its incidence and prevalence remain unknown. Several previous reports focused on the prevalence of BHD syndrome in patients with spontaneous pneumothorax [18, 19] or family history [5, 15, 16]. Recently, Hu et al. conducted a literature review of a large BHD syndrome cohort (120 families with 221 cases) in China [20]. However, they collected information using only published data; hence, the research was not representative of the nationwide data. In South Korea, Lee et al. reported only 12 patients (10 patients confirmed by FLCN gene test) who had BHD syndrome in a single largest tertiary hospital [21], suggesting the rarity of this condition. Our current data showed that BHD syndrome is ultrarare in South Korea, with a prevalence rate of only 5.67 per 10 million. As mentioned earlier, defining BHD syndrome cases using the ICD code alone seemed inadequate because it might omit other patients with BHD syndrome, leading to bias in evaluating epidemiologic data. In addition, patients with BHD syndrome who did not undergo the FLCN gene test were excluded in our analysis; this exclusion might have led to the underestimation of actual epidemiology. However, our data might serve as a reference for understanding this rare disease in South Korea.

Clinical manifestations of patients with BHD syndrome may also differ in terms of ethnicity [20, 22]. Kunogi et al. evaluated 30 Japanese patients with BHD syndrome and reported that while nearly all patients (96.7%) experienced pneumothorax, only 7 (23.3%) had skin lesion, and 2 (6.7%) had renal tumor [22]. Hu et al. investigated 221 Chinese patients with BHD syndrome and showed prevalence of pneumothorax (71.0%), skin lesion (18.1%), and renal cancer (3.6%) [20]. Thus, Asian patients might have a higher prevalence of pneumothorax and a lower incidence of cutaneous and renal manifestations than Western patients [4, 23–25]. Similarly, our current study found that pneumothorax occurred in over half of the patients (58.8%), but skin lesion (fibrofolliculoma, trichodiscoma, or accrocardon) and ureter and bladder cancer only accounted for 9 (34.6%) and 3 patients (11.5%), respectively. Recently, Liu et al. analyzed 51 Chinese patients with BHD syndrome and showed that Chinese patients had FLCN gene mutant loci that were different from those of Western patients [11]. This observation might possibly explain the ethnic difference. Notably, our current study showed several comorbidities, especially malignant neoplasm, in patients with BHD syndrome. Various tumors other than renal cancer might also occur in these patients [5, 24, 26, 27]. However, the gold standard or guidelines on how to optimally screening and manage these patients are still unavailable. Hence, further studies are needed.

Patients with BHD syndrome are predisposed to pneumothorax [1, 7]. Zbar et al. reported that the odds ratio for spontaneous pneumothorax in patients with BHD syndrome was 32 when compared with that in the general population [28]. In the current study, 65.4% of the patients experienced pneumothorax, comparable to other previous studies (approximately 24%–76%) [4, 10, 23, 29]. In addition, the median age of pneumothorax development was 43 years, which is also comparable to other previous studies with a relatively large number of patients [17, 23, 25]. Repetitive pneumothorax might also occur [23, 29]. Toro et al. showed that 101 episodes of pneumothorax (1 to 5 times in each patient) occurred in 48 patients with BHD syndrome [29]. In addition, Gupta et al. reported that the average number of pneumothorax was 3.6 in patients with BHD syndrome [23]. Our study population showed a similar recurrence rate of pneumothorax (58.8%). Notably, the hospital stay was longer in the second episode than in the first episode, suggesting that treatment might be difficult in patients with repetitive pneumothorax. Moreover, pneumothorax within 3 months of BHD syndrome diagnosis occurred in 13 patients (50% of study population), consistent with the previous study of Gupta et al. [23], which showed that pneumothorax was the presenting manifestation of BHD in 65% of their patients.

This study has some limitations. Considering that it used a nationwide medical claims database, BHD syndrome without FLCN gene mutation is not included in our dataset, thereby possibly omitting approximately 10% of patients with BHD syndrome [30]. Our study also did not include those with a family history of BHD syndrome and FLCN gene mutation, thereby reducing the representation of genetic features. Furthermore, if the clinician did not perform FLCN gene test for patients with suspected BHD syndrome, our criteria would underestimate the real prevalence. However, this study collected all FLCN gene tests performed in South Korea from 2016 to 2019, but only 26 patients were found. Moreover, we collected a maximum of 12.8-year follow-up data of patients suspected with BHD syndrome, including their clinical phenotypes combined with comorbidities and pneumothorax history, thereby showing the characteristics and clinical course of BHD syndrome.

Conclusions

In conclusion, the prevalence of BHD syndrome in South Korea is low. The patients with BHD syndrome are characterized by several comorbidities, including malignant neoplasm and repetitive pneumothorax.

Tests included in C5808 codes.

(DOCX)

Click here for additional data file.

Diseases included in rare incurable disease code.

NA: not applicable due to absence of a defined code.

(DOCX)

Click here for additional data file.

24 Feb 2022

24 Apr 2022

March 29th, 2022

Dong Keon Yon, MD, FACAAI

Academic Editor

PLOS ONE

Manuscript number: PONE-D-22-00655

Manuscript title: Epidemiology and Clinical Features of Birt-Hogg-Dubé Syndrome: A Nationwide Population-Based Study in South Korea

Dear Dong Keon Yon

We would like to thank you for the letter dated 24/02/2022, and the opportunity to resubmit a revised copy of this manuscript. We would also like to take this opportunity to express our thanks to the reviewers for the positive feedback and helpful comments for correction or modification. We have made every attempt to fully address these comments in the revised manuscript. Reviewer’s original comments are listed below, followed by our response to each comment. Changes made in the manuscript are marked in red. We very much hope the revised manuscript is accepted for publication in PLOS ONE.

The authors have declared that no competing interests exist. And the authors received no specific funding for this work. For data availability, HIRA (Health Insurance Review and Assessment Service) only provides summary data for researchers with limited permission to use the data. Therefore, we cannot share the minimal data set for this study. And we added the references which are well-performed studies using HIRA dataset which enable the national prevalence trend investigations.

Sincerely,

Ho Cheol Kim, MD, PhD

Department of Pulmonary and Critical Care Medicine,

Asan Medical Center,

88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea

Phone No: +82 02-3010-1494

Fax No: +82 02-3010-3130

Email Address: kimhocheol10@gmail.com

Response to Reviewers

Additional Editor Comments:

#1. Please discuss and cite the papers below, in Page 3; Line 18-19.

A. Woo A, Lee SW, Koh HY, Kim MA, Han MY, Yon DK. Incidence of cancer after asthma development: 2 independent population-based cohort studies. J Allergy Clin Immunol. 2021 Jan;147(1):135-143. doi: 10.1016/j.jaci.2020.04.041. Epub 2020 May 15. PMID: 32417133.

B. Yoo IK, Marshall DC, Cho JY, Yoo HW, Lee SW. N-Nitrosodimethylamine-contaminated ranitidine and risk of cancer in South Korea: a nationwide cohort study. Life Cycle 2021;1:e1. https://doi.org/10.54724/lc.2021.e1

- Answer: We have added these two papers as references in page 3, line 18-21.

In South Korea, the National Health Insurance Service is a universal insurance system that provides both inpatient and outpatient healthcare services for nearly all citizens, which enables to the investigation of the prevalence of disease in the whole national population.[12,13]

Reviewer #1: The authors aimed to investigate the epidemiologic data and clinical characteristics of Birt-Hogg-Dube syndrome of Korea. The most important limitation of the study is that, apart from the 26 cases detected in the study, the number of BHD syndrome cases in which the FLCN mutation is not studied cannot be determined, and this was stated by the authors in the limitations section. Except that the article is well designed and written.

- Answer: Thank you for your comment. This study investigates the prevalence of BHD syndrome and the associating malignancy and diseases. As the BHD syndrome could be diagnosed without the FLCN gene test, we agree that your point for omitting the BHD syndrome patients without FLCN gene as we discussed in limitation section. However, we thought that this method could reflect the malignancy and associating diseases of BHD syndrome even though the limitations, which help clinicians to consider the natural history of this syndrome.

Reviewer #2: Wonderful study especially because of it’s rarity. Just out of my own interest, would like to ask a couple of questions.

1. What was the X ray and HRCT pattern of these patients.

- Unfortunately, since we used the claim data called HIRA(Health Insurance Review & Assessment) data in our current study (ref: J Lipid Atheroscler. 2022;11:e1. Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research, by Kyoung et al.) we could not get information about the test results.

2. The study said around 58% of the patients had recurrent pneumothorax. How were they managed.

- Thanks for your comments. When we re-evaluated the patient with recurrent pneumothorax (n = 10), no patients underwent surgery and 70% (n = 7/10) were treated with chest tube insertion. We added this in the result section.

Submitted filename: Response to Reviewers 0328.docx

Click here for additional data file.

20 May 2022

Epidemiology and Clinical Features of Birt-Hogg-Dubé Syndrome: A Nationwide Population-Based Study in South Korea

PONE-D-22-00655R1

Dear Dr. Kim,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Dong Keon Yon, MD, FACAAI

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I congrature the authors on this mesmerizing paper.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: All issues have been adequately addressed.Hence,the article may be accepted for publication according to me.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

26 May 2022

PONE-D-22-00655R1

Epidemiology and Clinical Features of Birt-Hogg-Dubé Syndrome: A Nationwide Population-Based Study in South Korea

Dear Dr. Kim:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Dong Keon Yon

Academic Editor

PLOS ONE